KPV research on the gut and skin
KPV is a peptide consisting of three amino acids, the building blocks of proteins: lysine, proline, and valine. Its name uses their one-letter codes. The same sequence occurs at the end of alpha-MSH, a hormone involved in pigmentation and inflammation. That connection explains the name; it does not establish that administering KPV is safe.
Most evidence discussed here comes from cells and animals. FDA's July 2026 review found no human exposure data supporting the proposed uses. A result from a human cell grown in a dish is still laboratory evidence, rather than a trial treating a person.
Bowel inflammation experiments
In Dalmasso and colleagues' 2008 work, KPV entered intestinal and immune cells through a transporter called PepT1. A transporter is a protein that helps move material across a cell boundary. The experiments found reduced inflammatory signaling in cultured cells, alongside reductions in induced colitis in mice. Colitis means inflammation of the large bowel.
The research gives a plausible account of how KPV may affect these systems. FDA nevertheless notes that the exact molecular targets remain uncertain. A pathway observation should not be read as a complete explanation of what would happen in a person with bowel disease.
Another 2008 mouse study examined recovery from colitis. Mice receiving KPV recovered earlier and regained body weight more strongly in the experimental setting. Here weight regain accompanied recovery from illness. That is a different outcome from intentional weight reduction in an obesity trial, even though both can be summarized as weight change.
Delivery changes the experiment
Getting a peptide to the intended tissue is part of the research question. A 2017 study of targeted KPV delivery used hyaluronic-acid-coated nanoparticles within a gel in mice with induced colitis. The targeted preparation performed better than a non-targeted system. The carrier is part of the result, rather than an incidental detail.
It would therefore be misleading to credit any preparation called KPV with the same findings. Changing the carrier can change where material goes and how much arrives. The paper supports further investigation of that delivery system; it does not establish treatment of human ulcerative colitis.
Skin delivery research

A 2017 laboratory study used donated human skin to investigate KPV transport. Passive passage through intact skin was below the study's detection limit. Experimental methods that disrupted the barrier or used electrical assistance changed passage through the samples. This was not a clinical trial of a cream on living participants.
The finding illustrates a practical question about topical research: activity in a cell experiment does not establish that an ingredient crosses intact skin to reach the relevant tissue. It also cannot decide whether a particular commercial preparation works. The study measured transport under its own laboratory conditions, without providing a patient treatment outcome.
Safety information is missing
FDA's KPV briefing for the July 2026 advisory meeting describes gaps in clinical and nonclinical safety information. The review found no studies establishing human adverse-effect rates, and important toxicity, reproductive, and long-term safety tests were absent. Sparse reporting cannot be treated as reassurance when the underlying exposure information is missing.
The agency also considered possible immune responses, aggregation, and impurities. These are concerns that require investigation, rather than proof that a specific harm has occurred in people. There is no FDA-approved KPV prescribing label from which to draw established interactions or a patient dosing schedule. This page supplies neither.
Regulatory status
KPV is not an FDA-approved drug. FDA's safety-risk page, current as of April 22, 2026, lists KPV as nominated but withdrawn, not in the current Category 2 table. That date describes the page; it is not a published date for KPV's withdrawal. Withdrawing a nomination did not clear the substance for use.
In its draft policy published October 30, 2026, HHS said it did not intend to take enforcement action against state-licensed pharmacies and licensed physicians that compound KPV for an individual patient's prescription under the stated conditions. This remains a nonbinding draft, does not give FDA approval, and does not place KPV on FDA's 503A bulks list.
Only single-active-ingredient preparations can fall within that draft's conditions. Blends and 503B outsourcing facilities are outside its scope. A change in enforcement policy also does not convert the bowel or skin experiments into evidence of human treatment benefit. The source list keeps the scientific and policy documents separately identifiable.